Periodic Reporting for period 1 - GPR-ICI (Exploration of targeting GPR56 and its cancer cell ligand as a novel immune checkpoint inhibition strategy)

ICI has revolutionized cancer therapy over the last decade by harnessing the immune system to target cancer cells. It blocks immuno-suppressive receptors and their ligands, which normally reduce T cell activity and pro-inflammatory cytokine secretion, like interferon γ...